KR20010112364A - 신경 세포 분화를 촉진시키기 위한 환상 글리세로인산염및 그의 유사체를 포함하는 제약 조성물 - Google Patents

신경 세포 분화를 촉진시키기 위한 환상 글리세로인산염및 그의 유사체를 포함하는 제약 조성물 Download PDF

Info

Publication number
KR20010112364A
KR20010112364A KR1020017012158A KR20017012158A KR20010112364A KR 20010112364 A KR20010112364 A KR 20010112364A KR 1020017012158 A KR1020017012158 A KR 1020017012158A KR 20017012158 A KR20017012158 A KR 20017012158A KR 20010112364 A KR20010112364 A KR 20010112364A
Authority
KR
South Korea
Prior art keywords
disease
cyclic
disorder
pharmaceutical composition
neuronal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020017012158A
Other languages
English (en)
Korean (ko)
Inventor
미르 쉬니츠키
Original Assignee
폴리나 벤-아미, 야코브 코헨
예다 리서치 앤드 디벨럽먼트 캄파니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 폴리나 벤-아미, 야코브 코헨, 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 filed Critical 폴리나 벤-아미, 야코브 코헨
Publication of KR20010112364A publication Critical patent/KR20010112364A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020017012158A 1999-03-25 2000-03-24 신경 세포 분화를 촉진시키기 위한 환상 글리세로인산염및 그의 유사체를 포함하는 제약 조성물 Withdrawn KR20010112364A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL12917899A IL129178A0 (en) 1999-03-25 1999-03-25 Induction of nerve generation
IL129178 1999-03-25
PCT/IL2000/000185 WO2000057865A2 (en) 1999-03-25 2000-03-24 Pharmaceutical compositions comprising cyclic glycerophosphates and analogs thereof for promoting neural cell differentiation

Publications (1)

Publication Number Publication Date
KR20010112364A true KR20010112364A (ko) 2001-12-20

Family

ID=11072645

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017012158A Withdrawn KR20010112364A (ko) 1999-03-25 2000-03-24 신경 세포 분화를 촉진시키기 위한 환상 글리세로인산염및 그의 유사체를 포함하는 제약 조성물

Country Status (16)

Country Link
US (1) US6914056B1 (cg-RX-API-DMAC7.html)
EP (1) EP1162959B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002540146A (cg-RX-API-DMAC7.html)
KR (1) KR20010112364A (cg-RX-API-DMAC7.html)
CN (1) CN1348375A (cg-RX-API-DMAC7.html)
AT (1) ATE290385T1 (cg-RX-API-DMAC7.html)
AU (1) AU768911B2 (cg-RX-API-DMAC7.html)
BR (1) BR0009296A (cg-RX-API-DMAC7.html)
CA (1) CA2368597A1 (cg-RX-API-DMAC7.html)
DE (1) DE60018554T2 (cg-RX-API-DMAC7.html)
HK (1) HK1042038A1 (cg-RX-API-DMAC7.html)
IL (1) IL129178A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA01009650A (cg-RX-API-DMAC7.html)
NZ (1) NZ514525A (cg-RX-API-DMAC7.html)
RU (1) RU2247557C2 (cg-RX-API-DMAC7.html)
WO (1) WO2000057865A2 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69912808T2 (de) 1999-12-08 2004-09-30 Centre National De La Recherche Scientifique (C.N.R.S.) Verwendung von Hymenialdisin und dessen Derivaten zur Herstellung therapeutischer Mittel
JP4836345B2 (ja) * 2001-04-13 2011-12-14 きみ子 室伏 環状ホスファチジン酸誘導体を含む神経細胞の生存促進剤
JP4815063B2 (ja) * 2001-04-13 2011-11-16 きみ子 室伏 環状ホスファチジン酸を含むグリア細胞の増殖、分化及び/又は生存の促進のための薬剤
IL148668A0 (en) * 2002-03-13 2002-09-12 Yeda Res & Dev Derivatives of 1,3-cyclic propandiol phosphate and their action in differentiation therapy
IL148665A0 (en) * 2002-03-13 2002-09-12 Yeda Res & Dev Derivatives of 1,3-cyclic propandiol phate and their action as cell stimulants
AU2003220521A1 (en) * 2002-03-27 2003-10-13 Smithkline Beecham Corporation Methods of treatment with lxr modulators
JP4162927B2 (ja) 2002-06-11 2008-10-08 きみ子 室伏 カルバ環状ホスファチジン酸誘導体
US8101552B2 (en) * 2005-03-14 2012-01-24 Yeda Research And Development Company Ltd. Cyclic phosphates as plant growth regulators
ES2518371T3 (es) * 2006-04-26 2014-11-05 Toyama Chemical Co., Ltd. Inductor de la neurogénesis o agente terapéutico para la neuropatía que comprende un derivado de éter alquílico o una sal del mismo
KR20090097943A (ko) * 2006-12-28 2009-09-16 오짜노미즈 유니버시티 환상 포스파티딘산 유도체를 포함하는 진통제
EP2389348B1 (en) * 2009-01-09 2017-11-15 Sigma-Aldrich Co. LLC Process for the synthesis of beta glycerol phosphate
WO2011065480A1 (ja) * 2009-11-26 2011-06-03 国立大学法人お茶の水女子大学 神経細胞死抑制剤
WO2014115885A1 (ja) 2013-01-28 2014-07-31 国立大学法人お茶の水女子大学 脱髄疾患治療薬
EP2807925A1 (en) * 2013-05-26 2014-12-03 Symrise AG Antimicrobial compositions
EP3386995A1 (en) * 2015-12-08 2018-10-17 Retrophin, Inc. Cyclic phosphates and cyclic phosphoramidates for the treatment of neurologic disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL63037A (en) * 1981-06-04 1985-12-31 Israel State Dioxaphosphorinanes,their preparation and pharmaceutical and veterinary compositions containing them
US5565439A (en) * 1992-11-24 1996-10-15 The Procter & Gamble Company Methods of using lysophosphatidic acid for treating hyperproliferative conditions
JPH06228169A (ja) * 1993-02-05 1994-08-16 Sagami Chem Res Center 1−o−アシルグリセロール2,3−ホスフェートの製造法
JPH07149772A (ja) * 1993-11-26 1995-06-13 Sagami Chem Res Center タンパク質リン酸化酵素cの活性促進剤
JPH07258278A (ja) * 1994-03-18 1995-10-09 Sagami Chem Res Center 1−O−アシルグリセロール−2,3−ホスフェート誘導体を有効成分とするDNAポリメラーゼαの阻害剤
JPH0925235A (ja) * 1995-07-13 1997-01-28 Sagami Chem Res Center 1−o−アシルグリセロール−2,3−ホスフェート誘導体を有効成分とするがん転移抑制剤
US6150345A (en) * 1998-08-10 2000-11-21 Regents Of The University Of California Methods for promoting survival of myelin producing cells
IL129179A0 (en) 1999-03-25 2000-02-17 Yeda Res & Dev Cyclic glycerophosphates and analogs thereof

Also Published As

Publication number Publication date
RU2247557C2 (ru) 2005-03-10
AU3451700A (en) 2000-10-16
WO2000057865A9 (en) 2001-11-15
CN1348375A (zh) 2002-05-08
EP1162959B1 (en) 2005-03-09
NZ514525A (en) 2003-10-31
MXPA01009650A (es) 2002-07-02
AU768911B2 (en) 2004-01-08
WO2000057865A3 (en) 2001-06-28
JP2002540146A (ja) 2002-11-26
BR0009296A (pt) 2001-12-18
HK1042038A1 (zh) 2002-08-02
DE60018554D1 (de) 2005-04-14
US6914056B1 (en) 2005-07-05
WO2000057865A2 (en) 2000-10-05
CA2368597A1 (en) 2000-10-05
EP1162959A2 (en) 2001-12-19
ATE290385T1 (de) 2005-03-15
IL129178A0 (en) 2000-02-17
DE60018554T2 (de) 2006-04-13

Similar Documents

Publication Publication Date Title
EP1162959B1 (en) Pharmaceutical compositions comprising cyclic glycerophosphates and analogs thereof for promoting neural cell differentiation
Shaikh et al. The pathways mediating affective defense and quiet biting attack behavior from the midbrain central gray of the cat: an autoradiographic study
DE69433560T2 (de) Valproinsäure kovalent gebunden an einem lysophospholipid
US4263286A (en) Therapeutic agent for consciousness disorder and perception and movement disorder
AU733880B2 (en) Naaladase compositions and methods for treating glutamate abnormality and effecting neuronal activity in animals
EP0711559B1 (en) Use of phosphatidylserines for the manufacture of a medicament for improving cerebration
Lømo et al. Acetylcholine sensitivity of developing ectopic nerve‐muscle junctions in adult rat soleus muscles.
US8017597B2 (en) Analgesic agent comprising cyclic phosphatidic acid derivative
HU193302B (en) Process for producing phospholipide compositions and pharmaceutical compositions containing them as active agents
JP3036881B2 (ja) ビロバリデ誘導体、この用途及びこれを含有する薬剤組成物
JP2002514185A (ja) NAALADase阻害剤を用いる強迫性障害の治療の医薬組成物及び方法
Vogt Release from brain tissue of compounds with possible transmitter function: interaction of drugs with these substances
Curtis Gamma-aminobutyric and glutamic acids as mammalian central transmitters
JPH0640914A (ja) フィソスチグミンの新誘導体、それらの用途及びそれらを含む製薬組成物
Oakes et al. Effect of some anticancer drugs on the surface membrane electrical properties of differentiated murine neuroblastoma cells
Taylor et al. Release of acetylcholinesterase from the guinea-pig substantia nigra during peripheral nerve stimulation
De la Torre Effect of LSD-25 on the septal region of the rat brain
CN106668035A (zh) 一种抗癫痫药物组合物
US20060040901A1 (en) Derivatives of 1,3-cyclic propandiol phosphate and their action as cell stimulants
Brundin et al. Functional and morphological comparisons between cochlear outer hair cells and muscle tissues in the guinea‐pig
CHOLINERGIC InstituGes of Pharmacology and Anatoliy, Faculty of Veterinary, ledicine, University of ilessina and Institute of Pharmacology, Faculty of Hlledicine, Catanzaro, Italy
Kowalczyk et al. PS-17-3 Influence of cholecystokinin (CCK-8) and yohimbine on supraspinal modulation of nociceptive process
Liu PS-17-4 The possible mechanism of morphine tolerance
PARKASH ELECTROENCEPHALOGRAPHIC RESPONSE OF BRAIN LOCI TO LITHIUM AND NOMIFENSINE
Clarke The effect of vincristine sulfate on the metabolism of phospholipids in skeletal muscle of the rat

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20010924

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid